Significance of Uracil/Tegafur for Preventing Intravesical Recurrence of Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Current Urology, 05/25/2012

Despite the significant induction of γ–butyrolactone (GBL), adjuvant uracil/tegafur (UFT) therapy failed to show a preventive effect on intravesical recurrence of non–muscle invasive urothelial carcinoma of the bladder. Therefore, the authors should consider enhancing the anti–angiogenic effect of GBL using an alternative administration schedule of UFT.

Print Article Summary Cat 2 CME Report